AU773038B2 - Aminosterol compounds and uses thereof - Google Patents
Aminosterol compounds and uses thereof Download PDFInfo
- Publication number
- AU773038B2 AU773038B2 AU55575/99A AU5557599A AU773038B2 AU 773038 B2 AU773038 B2 AU 773038B2 AU 55575/99 A AU55575/99 A AU 55575/99A AU 5557599 A AU5557599 A AU 5557599A AU 773038 B2 AU773038 B2 AU 773038B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- aminosterol
- acceptable salt
- following structure
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000000813 microbial effect Effects 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 101100297395 Caenorhabditis elegans pha-4 gene Proteins 0.000 claims 1
- 241000209094 Oryza Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 15
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 15
- 229950001248 squalamine Drugs 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
- 229920000768 polyamine Polymers 0.000 description 11
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical group NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 11
- 235000011056 potassium acetate Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 150000003431 steroids Chemical class 0.000 description 10
- 238000004896 high resolution mass spectrometry Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 229940054441 o-phthalaldehyde Drugs 0.000 description 6
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 229940063673 spermidine Drugs 0.000 description 6
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000782099 Squaliformes Species 0.000 description 4
- 241000251778 Squalus acanthias Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005100 correlation spectroscopy Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 4
- 229940063675 spermine Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- -1 phenyl-hexyl Chemical group 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- 101100226769 Caenorhabditis elegans fax-1 gene Proteins 0.000 description 2
- 241000157857 Dendrobatidae Species 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091006649 SLC9A3 Proteins 0.000 description 2
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000012581 double quantum filtered COSY Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000480567 Pseudomonas aeruginosa C Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9633798P | 1998-08-12 | 1998-08-12 | |
| US60/096337 | 1998-08-12 | ||
| PCT/US1999/018322 WO2000009137A2 (en) | 1998-08-12 | 1999-08-12 | Aminosterol compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5557599A AU5557599A (en) | 2000-03-06 |
| AU773038B2 true AU773038B2 (en) | 2004-05-13 |
Family
ID=22256894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU55575/99A Ceased AU773038B2 (en) | 1998-08-12 | 1999-08-12 | Aminosterol compounds and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6388108B1 (enExample) |
| EP (1) | EP1105407B1 (enExample) |
| JP (1) | JP2002522501A (enExample) |
| AT (1) | ATE375359T1 (enExample) |
| AU (1) | AU773038B2 (enExample) |
| CA (1) | CA2339174C (enExample) |
| DE (1) | DE69937301T2 (enExample) |
| WO (1) | WO2000009137A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| MXPA03008085A (es) * | 2001-03-21 | 2004-03-10 | Leo Pharma As | Derivados de acido fusidico poliaminados novedosos. |
| CN100491392C (zh) * | 2002-04-05 | 2009-05-27 | 利奥制药有限公司 | 支链多胺甾体衍生物 |
| US20070129690A1 (en) | 2005-12-02 | 2007-06-07 | Joel Rosenblatt | Catheter with polymeric coating |
| WO2008038965A1 (en) * | 2006-09-26 | 2008-04-03 | Kyungpook National University Industry-Academic Cooperation Foundation | 7alpha-aminosteroid derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for anticancer or antibiotics containing the same as an active ingredient |
| CN101600429A (zh) * | 2006-12-08 | 2009-12-09 | 哈多技术有限公司 | 治疗和预防传染性疾病的胆固醇胺 |
| US20080188830A1 (en) * | 2007-02-06 | 2008-08-07 | Arrow International, Inc. | Selectively reinforced medical devices |
| WO2009032321A2 (en) * | 2007-09-06 | 2009-03-12 | Genaera Corporation | A method for treating diabetes |
| CA2711807A1 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| WO2009090063A1 (en) * | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| WO2010039828A1 (en) * | 2008-10-01 | 2010-04-08 | Teleflex Medical Incorporated | Article containing segregated biguanide and lewis acid |
| WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| US8623416B2 (en) * | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| MX356006B (es) * | 2013-10-18 | 2018-04-24 | Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C | Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos. |
| EP3515450A4 (en) * | 2016-09-21 | 2020-07-29 | Mount Desert Island Biological Laboratory | METHOD AND COMPOSITIONS FOR STIMULATING AND REINFORCING TISSUE REGENERATION |
| US11083735B2 (en) | 2017-09-08 | 2021-08-10 | Enterin, Inc. | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721226A (en) * | 1993-03-10 | 1998-02-24 | Magainin Pharmaceuticals Inc. | Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives |
| US5737691A (en) * | 1995-07-14 | 1998-04-07 | Motorola, Inc. | System and method for allocating frequency channels in a two-way messaging network |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) * | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5840936A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| DK0910382T3 (da) * | 1996-04-26 | 2003-10-06 | Genaera Corp | Squalamin i kombination med andre anticancermidler til behandling af tumorer |
| US6262283B1 (en) * | 1996-12-06 | 2001-07-17 | Magainin Pharmaceuticals Inc. | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
-
1999
- 1999-08-12 EP EP99942130A patent/EP1105407B1/en not_active Expired - Lifetime
- 1999-08-12 CA CA002339174A patent/CA2339174C/en not_active Expired - Fee Related
- 1999-08-12 US US09/762,999 patent/US6388108B1/en not_active Expired - Fee Related
- 1999-08-12 DE DE69937301T patent/DE69937301T2/de not_active Expired - Lifetime
- 1999-08-12 JP JP2000564639A patent/JP2002522501A/ja active Pending
- 1999-08-12 AT AT99942130T patent/ATE375359T1/de not_active IP Right Cessation
- 1999-08-12 AU AU55575/99A patent/AU773038B2/en not_active Ceased
- 1999-08-12 WO PCT/US1999/018322 patent/WO2000009137A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721226A (en) * | 1993-03-10 | 1998-02-24 | Magainin Pharmaceuticals Inc. | Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives |
| US5733899A (en) * | 1993-03-10 | 1998-03-31 | Magainin Pharmaceuticals Inc. | Method for treating infection using steroid based pharmaceutical compositions |
| US5737691A (en) * | 1995-07-14 | 1998-04-07 | Motorola, Inc. | System and method for allocating frequency channels in a two-way messaging network |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000009137A3 (en) | 2000-05-18 |
| DE69937301T2 (de) | 2008-08-14 |
| WO2000009137A2 (en) | 2000-02-24 |
| JP2002522501A (ja) | 2002-07-23 |
| US6388108B1 (en) | 2002-05-14 |
| EP1105407A4 (en) | 2004-03-17 |
| ATE375359T1 (de) | 2007-10-15 |
| EP1105407B1 (en) | 2007-10-10 |
| CA2339174A1 (en) | 2000-02-24 |
| EP1105407A2 (en) | 2001-06-13 |
| DE69937301D1 (de) | 2007-11-22 |
| CA2339174C (en) | 2009-01-06 |
| AU5557599A (en) | 2000-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU773038B2 (en) | Aminosterol compounds and uses thereof | |
| Moore et al. | Squalamine: an aminosterol antibiotic from the shark. | |
| EP0637243B1 (en) | Novel aminosterol antibiotic | |
| US5583239A (en) | Antimicrobial sterol conjugates | |
| EP0014815A2 (de) | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen | |
| DE3100974A1 (de) | Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente | |
| GB2206119A (en) | A new cyclosporin derivative with modified "8-amino acid" | |
| JP2009102446A (ja) | 抗菌活性を有する半合成グリコペプチド | |
| DE3888357T2 (de) | Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen. | |
| WO2007038868A2 (en) | Novel enediyne compound and uses thereof | |
| WO2010032269A2 (en) | Anti-inflammatory activity of the iridoid glycosides | |
| DE68921128T2 (de) | Pipocolinsäure enthaltende cyclische Peptolide, ihre Herstellung und sie enthaltende Zusammensetzungen. | |
| EP0792886A1 (en) | Novel peptide and therapeutic agent | |
| Diaz et al. | Studies on the relationship of structure to antimicrobial properties of diterpenoid compounds from Sideritis | |
| US5834453A (en) | Methods for the manufacture and use of antimicrobial sterol conjugates | |
| JP5763082B2 (ja) | 新規のバシトラシン抗生物質 | |
| JP4195089B2 (ja) | 亜酸化物単位から製造される巨大環式化合物 | |
| AT402822B (de) | Sdk peptide, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen | |
| EP0307553B1 (de) | Modifizierte Splenopentine, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE3887292T2 (de) | Antibiotische Verbindungen, genannt A/16686-Faktoren A'1,A'2 und A'3. | |
| EP1572226B1 (de) | Peptide mit hohem cysteingehalt | |
| CN120699105B (zh) | 一种氘代抗菌肽及其组合物和应用 | |
| JPH107631A (ja) | 抗菌、抗真菌および抗原虫活性を有するカルニチンのビスアルカノイルエステル | |
| DE69116383T2 (de) | Hexapeptidderivate von teicoplanin und verfahren zu deren herstellung | |
| JP3135491B2 (ja) | 新規抗生物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: GENAERA CORPORATION Free format text: FORMER NAME: MAGAININ PHARMACEUTICALS, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |